Jeito
Overview
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access around the world, particularly in Europe and the United States. Jeito Capital is based in Paris with a presence in Europe and the United States.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Adcendo | Apr 2026 | Series C | Lead |
| Alveus Therapeutics | Feb 2026 | Series A Extension | Co-investor |
| Odyssey | Sep 2025 | Series D | Co-investor |
| ReproNovo | May 2025 | Series A | Lead |
| Azafaros | May 2025 | Series B | Lead |
Key People
Rafaèle Tordjman
Founder CEO
Sabine Dandiguian
Managing Partner
Pascal Touchon
Operating Partner
Ksenija Pavletic
Partner Investor, CCO
Daniel Wolle
Principal
Julien ELRIC
Senior Principal
Mehdi AINOUCHE
Senior Principal
Annette Clancy
Operational Investor
Rachel Mears
Investor - Life Sciences
Claudio Costa-Neto
Chief Scientific Officer
Julie Darbellay
Investor Relations Jeito
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
